抄録
Pancreatic islet transplantation has emerged as an eff ective treatment for type 1 diabetes patients with severe hypoglycemic unawareness. Islet transplants, though signifi cantly improving, are still mostly done on an experimental basis. We have started a phase-II clinical trial in type 1 diabetes mellitus patients for islet transplantation using donors after brain death and donors after cardiac death to evaluate a protocol involving induction of ATG and inhibition of TNF. Islet transplantation must be conducted under the new Regenerative Medicine Law in Japan, which went into eff ect in November 2014. The introduction of the regenerative medicine approach is expected to accelerate the development of islet transplantation. In this review, we outline a current status of islet transplantation and the future prospects.
